Information updates

HAE Day - Monday 16 May 2022

Hereditary Angioedema, commonly known as HAE, has been classified as a complement deficiency, which is a type of primary immunodeficiency, and occurs in around one in 50,000 people.  People with HAE have unpredictable, recurrent and rapid swellings, which may involve the skin, gut and airway. HAE attacks interfere with daily life and can be life threatening.

HAE Day 2022 aims to increase awareness of HAE in health professionals and the community. A media release for HAE Day 2022 is available here. 

pdfHAE Day 2022 Media Release210.21 KB

The patient organisation for HAE in Australia and New Zealand is HAE Australasia, and we commend them on their outstanding work in advocacy and patient support.

Our intention is that the ASCIA Immunodeficiency Strategy for Australia and New Zealand supports the important work of HAE Australasia and other patient support organisations and enables key issues to be addressed, including early diagnosis of HAE and access to appropriate treatments.

The ASCIA Immunodeficiency Strategy addresses the need for:

  • Improved education for health professionals to recognise early warning signs of HAE and other primary immunodeficiencies;
  • Improved access to paediatric and adult clinical immunology/allergy specialists;
  • Equitable access to funded treatments in rural, remote and regional centres, as well as urban areas.

The ASCIA Immunodeficiency Strategy for Australia and New Zealand was launched on 29 April 2022. This launch has resulted in substantial media coverage, particularly regarding newborn screening for Severe Combined Immune Deficiency, commonly known as SCID. The purpose of the Strategy is to improve the health and wellbeing of people living with primary immunodeficiencies, (also known as inborn errors of immunity), and minimise the burden on individuals, carers, health services and the community.

The Strategy is focused on primary immunodeficiencies, a diverse group of more than 400 potentially serious, chronic illnesses due to inherited absence or dysregulation of parts of the immune system, that can lead to reduced quality of life and life expectancy.

Information about HAE is available on the ASCIA website:

This news item was issued on 16 May 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia